Literature DB >> 21129329

Models of glucagon secretion, their application to the analysis of the defects in glucagon counterregulation and potential extension to approximate glucagon action.

Leon S Farhy1, Anthony L McCall.   

Abstract

This review analyzes an interdisciplinary approach to the pancreatic endocrine network-like relationships that control glucagon secretion and glucagon counterregulation (GCR). Using in silico studies, we show that a pancreatic feedback network that brings together several explicit interactions between islet peptides and blood glucose reproduces the normal GCR axis and explains its impairment in diabetes. An α-cell auto-feedback loop drives glucagon pulsatility and mediates triggering of GCR by hypoglycemia by a rapid switch-off of β-cell signals. The auto-feedback explains the enhancement of defective GCR in β-cell deficiency by a switch-off of signals in the pancreas that suppress α cells. Our models also predict that reduced β-cell activity decreases and delays the GCR. A key application of our models is the in silico simulation and testing of possible scenarios to repair defective GCR in β-cell deficiency. In particular, we predict that partial suppression of hyperglucagonemia may repair the impaired GCR. We also outline how the models can be extended and tested using human data to become a part of a larger construct including the regulation of the hepatic glucose output by the pancreas, circulating glucose, and incretins. In conclusion, a model of the normal GCR control mechanisms and their dysregulation in insulin-deficient diabetes is proposed and partially validated. The model components are clinically measurable, which permits its application to the study of the abnormalities of the human endocrine pancreas and their role in the progression of many diseases, including diabetes, metabolic syndrome, polycystic ovary syndrome, and others. It may also be used to examine therapeutic responses.
© 2010 Diabetes Technology Society.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21129329      PMCID: PMC3005044          DOI: 10.1177/193229681000400608

Source DB:  PubMed          Journal:  J Diabetes Sci Technol        ISSN: 1932-2968


  68 in total

1.  Expression of the five different somatostatin receptor subtypes in endocrine cells of the pancreas.

Authors:  G M Portela-Gomes; M Stridsberg; L Grimelius; K Oberg; E T Janson
Journal:  Appl Immunohistochem Mol Morphol       Date:  2000-06

2.  Activation of autonomic nerves and the adrenal medulla contributes to increased glucagon secretion during moderate insulin-induced hypoglycemia in women.

Authors:  P J Havel; B Ahren
Journal:  Diabetes       Date:  1997-05       Impact factor: 9.461

3.  Somatostatin inhibits insulin and glucagon secretion via two receptors subtypes: an in vitro study of pancreatic islets from somatostatin receptor 2 knockout mice.

Authors:  M Z Strowski; R M Parmar; A D Blake; J M Schaeffer
Journal:  Endocrinology       Date:  2000-01       Impact factor: 4.736

4.  Distribution of glucagon receptors on hormone-specific endocrine cells of rat pancreatic islets.

Authors:  T J Kieffer; R S Heller; C G Unson; G C Weir; J F Habener
Journal:  Endocrinology       Date:  1996-11       Impact factor: 4.736

Review 5.  Glucose sensing in pancreatic beta-cells: a model for the study of other glucose-regulated cells in gut, pancreas, and hypothalamus.

Authors:  F C Schuit; P Huypens; H Heimberg; D G Pipeleers
Journal:  Diabetes       Date:  2001-01       Impact factor: 9.461

6.  Dose-response for glucagonostatic effect of amylin in rats.

Authors:  B R Gedulin; T J Rink; A A Young
Journal:  Metabolism       Date:  1997-01       Impact factor: 8.694

Review 7.  Stimulus-secretion coupling in pancreatic beta cells.

Authors:  F M Ashcroft; P Proks; P A Smith; C Ammälä; K Bokvist; P Rorsman
Journal:  J Cell Biochem       Date:  1994       Impact factor: 4.429

8.  Differences in glucose transporter gene expression between rat pancreatic alpha- and beta-cells are correlated to differences in glucose transport but not in glucose utilization.

Authors:  H Heimberg; A De Vos; D Pipeleers; B Thorens; F Schuit
Journal:  J Biol Chem       Date:  1995-04-14       Impact factor: 5.157

9.  Effects of hexoses and their derivatives on glucagon secretion from isolated perfused rat pancreas.

Authors:  Y Sumida; T Shima; K Shirayama; M Misaki; K Miyaji
Journal:  Horm Metab Res       Date:  1994-05       Impact factor: 2.936

10.  Exogenous insulin dose-dependently suppresses glucopenia-induced glucagon secretion from perfused rat pancreas.

Authors:  K Ito; H Maruyama; H Hirose; K Kido; K Koyama; K Kataoka; T Saruta
Journal:  Metabolism       Date:  1995-03       Impact factor: 8.694

View more
  8 in total

Review 1.  Optimizing reduction in basal hyperglucagonaemia to repair defective glucagon counterregulation in insulin deficiency.

Authors:  L S Farhy; A L McCall
Journal:  Diabetes Obes Metab       Date:  2011-10       Impact factor: 6.577

2.  Quantification of the glycemic response to microdoses of subcutaneous glucagon at varying insulin levels.

Authors:  Joseph El Youssef; Jessica R Castle; Parkash A Bakhtiani; Ahmad Haidar; Deborah L Branigan; Matthew Breen; W Kenneth Ward
Journal:  Diabetes Care       Date:  2014-08-19       Impact factor: 19.112

Review 3.  Safe glycemic management during closed-loop treatment of type 1 diabetes: the role of glucagon, use of multiple sensors, and compensation for stress hyperglycemia.

Authors:  W Kenneth Ward; Jessica R Castle; Joseph El Youssef
Journal:  J Diabetes Sci Technol       Date:  2011-11-01

Review 4.  Treating type 1 diabetes: from strategies for insulin delivery to dual hormonal control.

Authors:  A L McCall; L S Farhy
Journal:  Minerva Endocrinol       Date:  2013-06       Impact factor: 2.184

Review 5.  Insulin therapy and hypoglycemia.

Authors:  Anthony L McCall
Journal:  Endocrinol Metab Clin North Am       Date:  2012-04-17       Impact factor: 4.741

6.  Association of Basal hyperglucagonemia with impaired glucagon counterregulation in type 1 diabetes.

Authors:  Leon S Farhy; Alice Chan; Marc D Breton; Stacey M Anderson; Boris P Kovatchev; Anthony L McCall
Journal:  Front Physiol       Date:  2012-02-28       Impact factor: 4.566

7.  Mathematical Model of Glucagon Kinetics for the Assessment of Insulin-Mediated Glucagon Inhibition During an Oral Glucose Tolerance Test.

Authors:  Micaela Morettini; Laura Burattini; Christian Göbl; Giovanni Pacini; Bo Ahrén; Andrea Tura
Journal:  Front Endocrinol (Lausanne)       Date:  2021-03-22       Impact factor: 5.555

8.  Targeting SUR1/Abcc8-type neuroendocrine KATP channels in pancreatic islet cells.

Authors:  Yumiko Nakamura; Joseph Bryan
Journal:  PLoS One       Date:  2014-03-12       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.